Our portfolio

Built on the principles of speed, scale and equitable access, CEPI is supporting the research and development of a diverse portfolio of vaccine candidates based on a range of vaccine approaches. CEPI has to date advanced the development of over 20 vaccine candidates against our priority pathogens (Chikungunya, Lassa fever, MERS, Nipah, Rift Valley fever) and has also advanced the development of three rapid response platforms to develop vaccines against Disease X.

CEPI moved quickly and urgently to accelerate vaccine development in response to the COVID-19 crisis. We announced our first vaccine partnerships on 23 January 2020 when there were just 581 confirmed cases of COVID-19 globally, and swiftly built a diverse portfolio of investments in 14 COVID-19 vaccine candidates to maximise our chances of success. Three of these (Oxford/AZ, Moderna, and Novavax) have been granted emergency use listing by the World Health Organization (WHO) and are now preventing disease and death around the world. A further six are still being funded by CEPI, including some second generation and variant-proof vaccines.

CEPI is also supporting the development of broadly protective coronavirus vaccines as part of its plan to minimise the risk of future epidemic and pandemic threats.